1. Home
  2. ESPR vs PRQR Comparison

ESPR vs PRQR Comparison

Compare ESPR & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.87

Market Cap

898.5M

Sector

Health Care

ML Signal

HOLD

Logo ProQR Therapeutics N.V.

PRQR

ProQR Therapeutics N.V.

HOLD

Current Price

$2.33

Market Cap

250.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESPR
PRQR
Founded
2008
2012
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
898.5M
250.7M
IPO Year
2013
2014

Fundamental Metrics

Financial Performance
Metric
ESPR
PRQR
Price
$3.87
$2.33
Analyst Decision
Buy
Strong Buy
Analyst Count
7
7
Target Price
$6.86
$8.14
AVG Volume (30 Days)
6.5M
558.5K
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$303,802,000.00
$18,859,556.00
Revenue This Year
$25.45
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.83
N/A
52 Week Low
$0.69
$1.07
52 Week High
$4.13
$3.46

Technical Indicators

Market Signals
Indicator
ESPR
PRQR
Relative Strength Index (RSI) 61.15 53.75
Support Level $3.72 $2.15
Resistance Level $4.00 $2.42
Average True Range (ATR) 0.26 0.19
MACD 0.01 0.04
Stochastic Oscillator 75.24 79.70

Price Performance

Historical Comparison
ESPR
PRQR

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

About PRQR ProQR Therapeutics N.V.

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.

Share on Social Networks: